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Abstract: New pathways are being identified now on a regular
basis, and novel agents are being tested in a wide variety of
clinical trials for patients with advanced non-small cell lung
cancer. Excitement over progress in one area is tempered natu-
rally by disappointing results in other areas. Each year, leading
lung cancer experts meet in Santa Monica to discuss the progress
in the field of molecularly targeted therapy in non-small cell lung
cancer. Annual conferences similar to the one held in Santa
Monica serve mainly as a catalyst to promote new ideas and
foster active collaboration. We have invited participants to pro-
vide very brief succinct summaries of the presentations for this
supplement. The articles in this supplement should be viewed
more as meeting reports than as exhaustive and comprehensive
review articles.
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Just like every year over the past decade, leading expertswith special research interest in lung cancer from around
the world met again a few months ago in Santa Monica,
California, to discuss strategies for improving the outcomes
of patients with lung cancer using molecularly targeted ther-
apies. As has been made clear before, this is a large “work in
progress” meeting. New pathways are being identified now
on a regular basis, and novel agents are being tested in a wide
variety of clinical trials for patients with advanced non-small
cell lung cancer. Excitement over progress in one area is
tempered naturally by disappointing results in other areas.
Annual conferences similar to the one held in Santa Monica
serve mainly as a catalyst to promote new ideas and foster
active collaboration. Because the meeting is restricted to a
few individuals, we feel that this supplement on presentations
from the “Santa Monica Meeting” would be of great interest
to the oncology community. As before, we asked our con-
tributors to provide only very brief succinct summaries and
limit references and figures to a bare minimum. The articles
in this supplement should be viewed more as meeting reports
than as exhaustive and comprehensive review articles. We
hope you the readers of the Journal of Thoracic Oncology
will find the supplement instructive and useful. I am grateful
to the contributors for their help and to Drs. Paul Bunn, David
Johnson, and Roy Herbst for conceiving and organizing this
“Santa Monica Meeting” year after year.
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